News Articles and Montana BioScience Alliance Newsletters

TNX-4300’s Mechanism of Restoring Neuroplasticity Supports Development as a First-in-Class Oral Therapy for Depression, Bipolar Disorder, Alzheimer’s Disease and Parkinson’s Disease

Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039.

News, events, and SBIR/STTR Solicitations for May

A scientific team that includes University of Montana biologist Mark Grimes recently used artificial intelligence to better understand how protein groups in lung cancer cells regulate cell division and metabolism. The work may lead to greater understanding of lung cancer vulnerabilities and future anti-cancer therapies.

Viral clearance testing is a critical step in the development and production of biologics and other products that are derived from biological sources. GMP-compliant service provides the assurance that products have been thoroughly tested for the presence of viral contaminants, and that they are safe for use.

Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.

Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more

SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]

FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.

Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.

View the Spring 2023 Newsletter now!

View the Winter 2022 Newsletter now!